Standaert DG - Search Results

1

Fiber-modified adenovirus for central nervous system Parkinson's disease gene therapy.

Lewis TB, Glasgow JN, Harms AS, Standaert DG, Curiel DT. Lewis TB, et al. Among authors: standaert dg. Viruses. 2014 Aug 21;6(8):3293-310. doi: 10.3390/v6083293. Viruses. 2014. PMID: 25196484 Free PMC article.

2

Design of clinical trials of gene therapy in Parkinson disease.

Lewis TB, Standaert DG. Lewis TB, et al. Among authors: standaert dg. Exp Neurol. 2008 Jan;209(1):41-7. doi: 10.1016/j.expneurol.2007.08.012. Epub 2007 Aug 31. Exp Neurol. 2008. PMID: 17920590 Review.

3

Transcriptional dysregulation in a transgenic model of Parkinson disease.

Yacoubian TA, Cantuti-Castelvetri I, Bouzou B, Asteris G, McLean PJ, Hyman BT, Standaert DG. Yacoubian TA, et al. Among authors: standaert dg. Neurobiol Dis. 2008 Mar;29(3):515-28. doi: 10.1016/j.nbd.2007.11.008. Epub 2007 Nov 28. Neurobiol Dis. 2008. PMID: 18191405 Free PMC article.

4

Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy.

Lewis TB, Glasgow JN, Glandon AM, Curiel DT, Standaert DG. Lewis TB, et al. Among authors: standaert dg. PLoS One. 2010 Sep 17;5(9):e12672. doi: 10.1371/journal.pone.0012672. PLoS One. 2010. PMID: 20862245 Free PMC article.

5

Parkinson's disease, primates, and gene therapy: vive la différence?

Lewis TB, Standaert DG. Lewis TB, et al. Among authors: standaert dg. Mov Disord. 2011 Jan;26(1):2-3. doi: 10.1002/mds.23544. Epub 2010 Dec 17. Mov Disord. 2011. PMID: 21322013 Free PMC article. No abstract available.

6

Evaluation of TorsinA as a target for Parkinson disease therapy in mouse models.

Li X, Lee J, Parsons D, Janaurajs K, Standaert DG. Li X, et al. Among authors: standaert dg. PLoS One. 2012;7(11):e50063. doi: 10.1371/journal.pone.0050063. Epub 2012 Nov 21. PLoS One. 2012. PMID: 23185535 Free PMC article.

7

The gamma chain subunit of Fc receptors is required for alpha-synuclein-induced pro-inflammatory signaling in microglia.

Cao S, Standaert DG, Harms AS. Cao S, et al. Among authors: standaert dg. J Neuroinflammation. 2012 Nov 27;9:259. doi: 10.1186/1742-2094-9-259. J Neuroinflammation. 2012. PMID: 23186369 Free PMC article.

8

MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration.

Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, Cron RQ, Shacka JJ, Raman C, Standaert DG. Harms AS, et al. Among authors: standaert dg. J Neurosci. 2013 Jun 5;33(23):9592-600. doi: 10.1523/JNEUROSCI.5610-12.2013. J Neurosci. 2013. PMID: 23739956 Free PMC article.

9

Monocytes and Parkinson's disease: invaders from outside?

Harms AS, Standaert DG. Harms AS, et al. Among authors: standaert dg. Mov Disord. 2014 Sep;29(10):1242. doi: 10.1002/mds.25993. Epub 2014 Aug 14. Mov Disord. 2014. PMID: 25124371 No abstract available.

10

Fractalkine Signaling Regulates the Inflammatory Response in an α-Synuclein Model of Parkinson Disease.

Thome AD, Standaert DG, Harms AS. Thome AD, et al. Among authors: standaert dg. PLoS One. 2015 Oct 15;10(10):e0140566. doi: 10.1371/journal.pone.0140566. eCollection 2015. PLoS One. 2015. PMID: 26469270 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

281 results

Search Page